Treatment of hyperuricaemia and gout

Roddy, Edward; Doherty, Michael

doi:10.7861/clinmedicine.13-4-400

Cited by 17 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schlesinger, et al 23 showed that after adjusting for age and comorbidities, including hypertension, low-density lipoprotein, diabetes, depression, obesity, and chronic kidney disease, gout was still significantly associated with ED. To our knowledge, to date no causal study regarding 4 The .57)*** ‡ Patients with any 1 of the comorbidities (diabetes, ischemic heart disease, congestive heart failure, hypertension, depression, and chronic renal disease) were classified as the comorbidity group. # Incidence rate, per 10,000 person-years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gout and a Subsequent Increased Risk of Erectile Dysfunction in Men Aged 64 and Under: A Nationwide Cohort Study in Taiwan

Chen

Lin²,

Lu³

et al. 2015

J Rheumatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previous reports have focused on the pharmacological and nonpharmacological treatment of gout 2,3,4 . Gout frequently coexists with diabetes and hypertension, and is often neglected as a genuine risk factor for vascular disease 5,6 .…”

mentioning

confidence: 99%

Gout and a Subsequent Increased Risk of Erectile Dysfunction in Men Aged 64 and Under: A Nationwide Cohort Study in Taiwan

Chen

Lin²,

Lu³

et al. 2015

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…The daily dose of allopurinol recommended for reaching target values of uricemia is 100–600 mg, although sometimes it must be up to 900 mg in patients without impaired renal function. 46 Different studies show a dose–response effectiveness for allopurinol to achieve beneficial effects on blood pressure and endothelial function; in fact, a higher dosage of allopurinol (300 mg twice daily) has resulted in quality improvement of vascular biology and left ventricular hypertrophy. 47 In obese or hypertensive adolescents, the dosage of allopurinol administered was 200 mg twice daily, 48 , 49 but in older adults it seems necessary to increase the dosage to lower blood pressure values.…”

Section: Management Of Hyperuricemiamentioning

confidence: 99%

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia

Bove¹,

Cicero²,

Veronesi³

et al. 2017

VHRM

View full text Add to dashboard Cite

Several studies suggest that chronic hyperuricemia, the main precursor of gout, is involved in the pathogenesis of different systemic disorders that affect cardiovascular and renal systems, such as hypertension, obesity, hypercholesterolemia, atherosclerosis, metabolic syndrome, chronic heart failure, and chronic kidney disease. Recent epidemiological evidence has shown an increasing trend in the prevalence of hyperuricemia and gout in the Western world: a number of population-based studies estimate a prevalence of up to 21% for hyperuricemia and 1%–4% for gout. As such, early detection and careful management of this pathological condition is required, starting from lifestyle changes (mainly based on a diet low in red meat, sugars, and alcoholic beverages, with increased intake of vegetables, water, and vitamin C sources), adding specific drugs to lead serum uric acid (SUA) levels under the target value of 7 mg/dL. In particular, nonselective and selective XO inhibitors (allopurinol, oxypurinol, febuxostat) reduce SUA levels and the overproduction of reactive oxygen species, mainly related to XO overactivity that often causes inflammatory damage to the vascular endothelium. The effect of lowering SUA levels via XO inhibition includes an attenuation of oxidative stress and related endothelial dysfunction that largely contribute to the pathophysiology of metabolic syndrome and cardiovascular diseases. Therefore, the inhibition of XO overactivation seems to be an excellent therapeutic option to limit the harmful effects of excess UA and reactive oxygen species. In conclusion, rapid diagnosis and correct therapy for hyperuricemia may also improve the prevention and/or treatment of serious and multifactorial diseases. The available evidence supports the importance of promoting new experimental clinical trials to confirm the emerging antioxidant role of XO inhibitors, which could effectively contribute to cardiovascular and chronic kidney disease prevention.

show abstract

“…The overproduction of uric acid leads to hyperuricemia, which is a key cause of gout. Therefore, XO is considered the most promising target for treating this condition [2,3]. Allopurinol (Fig.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors

Chen

Zhang

Wang

et al. 2015

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Treatment of hyperuricaemia and gout

Cited by 17 publications

References 13 publications

Gout and a Subsequent Increased Risk of Erectile Dysfunction in Men Aged 64 and Under: A Nationwide Cohort Study in Taiwan

Gout and a Subsequent Increased Risk of Erectile Dysfunction in Men Aged 64 and Under: A Nationwide Cohort Study in Taiwan

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia

Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors

Contact Info

Product

Resources

About